Skip to main content

Characterization and Chemical Optimization of the D2 Dopamine Receptor-Selective Antagonist, ML321, Identifies Lead Compounds for the Clinical Treatment of Neuropsychiatric Disorders.

Publication ,  Journal Article
Nilson, AN; Dulcey Garcia, A; Free, RB; Boldizsar, N; Pearlstein, H; Rocereta, JA; Rodriguiz, RM; Lane, JR; Lee, KH; Shi, L; Wetsel, WC ...
Published in: FASEB J
May 2022

Schizophrenia is a devastating illness characterized by both positive (hallucinations, delusions) and negative (flat affect, decreased motivation) symptoms coupled with cognitive impairment. Current antipsychotic medications are effective in treating the positive symptoms through antagonism of the D2 dopamine receptor (D2R). However, antipsychotic treatment is also hindered by side-effects due to off-target activities at other GPCRs and unfavorable binding kinetics at the D2R. We have identified and characterized a novel D2R antagonist with high selectivity against other GPCRs - ML321. In functional profiling screens of up to 168 different GPCRs, ML321 showed little activity beyond potent inhibition of the D2R, and to a lesser extent the D3R, demonstrating exceptional GPCR selectivity. Schild-type functional assays revealed that ML321 acts as a competitive antagonist of the D2R while kinetic studies showed that ML321 exhibits slow-on and fast-off receptor binding rates; properties that are believed to limit extrapyramidal side-effects that are commonly observed with antipsychotics. In fact, using doses that were maximally effective in antipsychotic-predictive behavioral assays in rodents, ML321 promoted little to no catalepsy, suggesting that ML321 may produce less extrapyramidal side-effects in patients. Importantly, no other D2R antagonist exhibits this pharmacological and behavioral profile supporting its development into an advanced drug lead. While a promising therapeutic, ML321 has a short metabolic half-life, impeding its clinical development. A metabolite study revealed that the primary site of metabolism involves oxidation of the alkyl-thiophene portion of ML321. To create more metabolically stable derivatives, we iteratively designed and synthesized over 100 analogs with modifications focused on the alkyl-thiophene moiety. These analogs were pharmacologically characterized for both D2R binding affinity and function, and were also tested for metabolic stability, permeability, and solubility. These efforts have led to the optimization of ML321 into a collection of lead candidates that show similar pharmacological characteristics of ML321, but with marked increases in metabolic stability and ADME properties. Molecular docking and mutagenesis studies have led to a better understanding of how ML321 binds to the D2R, which will further assist in analog design and development. Together, these findings have advanced our understanding of ML321 structure-activity relationships, particularly around the alkyl-thiophene moiety, and have identified lead candidates for in vivo pharmacokinetic studies, thus representing substantial progress in the development of a new antipsychotic treatment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

FASEB J

DOI

EISSN

1530-6860

Publication Date

May 2022

Volume

36 Suppl 1

Location

United States

Related Subject Headings

  • Biochemistry & Molecular Biology
  • 3208 Medical physiology
  • 3101 Biochemistry and cell biology
  • 1116 Medical Physiology
  • 0606 Physiology
  • 0601 Biochemistry and Cell Biology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nilson, A. N., Dulcey Garcia, A., Free, R. B., Boldizsar, N., Pearlstein, H., Rocereta, J. A., … Sibley, D. R. (2022). Characterization and Chemical Optimization of the D2 Dopamine Receptor-Selective Antagonist, ML321, Identifies Lead Compounds for the Clinical Treatment of Neuropsychiatric Disorders. FASEB J, 36 Suppl 1. https://doi.org/10.1096/fasebj.2022.36.S1.R2720
Nilson, Ashley N., Andres Dulcey Garcia, R. B. Free, Noelia Boldizsar, Hannah Pearlstein, Julia A. Rocereta, Ramona M. Rodriguiz, et al. “Characterization and Chemical Optimization of the D2 Dopamine Receptor-Selective Antagonist, ML321, Identifies Lead Compounds for the Clinical Treatment of Neuropsychiatric Disorders.FASEB J 36 Suppl 1 (May 2022). https://doi.org/10.1096/fasebj.2022.36.S1.R2720.
Nilson AN, Dulcey Garcia A, Free RB, Boldizsar N, Pearlstein H, Rocereta JA, Rodriguiz RM, Lane JR, Lee KH, Shi L, Wetsel WC, Marugan JJ, Sibley DR. Characterization and Chemical Optimization of the D2 Dopamine Receptor-Selective Antagonist, ML321, Identifies Lead Compounds for the Clinical Treatment of Neuropsychiatric Disorders. FASEB J. 2022 May;36 Suppl 1.

Published In

FASEB J

DOI

EISSN

1530-6860

Publication Date

May 2022

Volume

36 Suppl 1

Location

United States

Related Subject Headings

  • Biochemistry & Molecular Biology
  • 3208 Medical physiology
  • 3101 Biochemistry and cell biology
  • 1116 Medical Physiology
  • 0606 Physiology
  • 0601 Biochemistry and Cell Biology